| 摘要 |
<p>The invention relates to tablets of the type containing a homogeneous dispersion of an active principle based on salbutamol or one of its derivatives in a hydrophilic matrix, providing:… - in vitro, for a sustained, steady and pH-independent release of the active principle during a time interval of approximately 12 hours,… - in vivo, for a zero-order kinetics of passage of the active principle into the body during a time interval of 6 hours,… the said matrix containing at least one swelling component and a diluent component in the weight ratio swelling component/diluent component of between 0.2 and 0.6, and preferably equal to approximately 0.4.</p> |
